

NIMISH GERA, P.H.D.

INDEPENDENT BIOTECH CONSULTANT

BOSTON, MA

Entrepreneurial biotech executive with broad expertise across various antibody-based modalities (**mono and bispecific antibodies, protein-fusions, and antibody-drug conjugates**) and therapeutic areas (**oncology, immunology, autoimmune and rare diseases**) at small (Mythic Therapeutics, Oncobiologics) and large (Alexion, Genentech) biotech.

- Experience with building and leading high performing discovery and development teams and managing internal and external collaborations in matrix industry settings.
- Successful track record of bringing multiple drugs to clinical trials, peer-reviewed publications, patents and chairing national and international meetings.
- Drive SAB, BoD, and stakeholder alignment to advance scientific strategy and due diligence for BD opportunities.
- Passionate about people management, mentoring and process optimization to accelerate drug development.

ANTIBODY DRUG CONJUGATES (ADCs)

- Championed discovery and preclinical development of MYTX-011 (anti-cMET ADC), leading molecular design, engineering, and pharmacology through IND-enabling studies, achieving robust translation to Phase I in NSCLC. Delivered three differentiated ADC development candidates in under six years leading research at Mythic Tx.
- Extensive experience with managing global CROs for mono and bispecific/biparatopic antibody conjugation with various linker payloads (MMAE, topoisomerase, tesirine etc.) and chemistry (hinge, site specific, lysine).
- Design of preclinical and IND enabling studies (mouse CDX, mouse PDX, cyno PK/PD, cyno DRF, GLP-tox) to evaluate efficacy and toxicity of ADCs with in-house/outsourced bioanalytical assay development.
- Development of protein characterization and cell-based assays (internalization, cytotoxicity, downregulation, recycling) to enable candidate selection.

BISPECIFIC ANTIBODIES

- Led gefurulumab (next-generation anti-C5 bispecific nanobody) from concept through development candidate nomination at Alexion, culminating in recent success in gMG with once-weekly self-administered subQ dosing.
- Experience with design of bispecific/biparatopic antibodies in various formats (common light chain, tandem VHH, appended IgG, scFv based) including AND/OR gating and Fc engineering for expanded MoAs with good developability.

ANTIBODY DISCOVERY and ENGINEERING

- Expert in in vivo (mouse, rabbit, llama, transgenic) and in vitro (phage/yeast display, naïve/immune libraries) antibody discovery across all formats (scFv, Fab, VHH) enabling unique discovery strategies tailored to project timelines.
- Successfully lead and manage global CROs structuring various discovery and engineering campaigns (epitope specific, stability, pH-dependence and conditional binders) through robust term sheet and SOW negotiations.
- Strategic oversight and execution of construct design and production across advanced modalities, including bispecifics, protein fusions, and ADCs, ensuring downstream manufacturability and differentiation.
- Deep operational and analytical experience integrating early-stage protein characterization (BLI, SPR, ELISA) with predictive developability workflows (SEC, BVP, CIC, HIC, CSI-BLI, AC-SINS, Apoha Liquid Brain) to de-risk candidates.

COMPANY BUILDING SUPPORT

- Demonstrated expertise in establishing and scaling laboratory operations in start-up and incubator settings, optimizing equipment workflows, infrastructure, and team composition to accelerate R&D readiness.
- Strong vendor and partner network enabling efficient lab setup, relocation, and operational execution.
- Strategic communicator skilled at translating complex science in antibodies, bispecifics, ADCs, and pharmacokinetics into clear insights for boards, investors, and cross-functional stakeholders.

MISCELLANEOUS

Short Course Instructor, Developability of Bispecific Antibodies, PEGS BOSTON AND PEGS EUROPE (2019 – Present)

Associate Editor, mAbs, and Peer Reviewer, VARIOUS SCIENTIFIC JOURNALS (2013 – Present)

Scientific Advisory Board Member, VARIOUS START-UPS IN ONCOLOGY AND IMMUNOLOGY (2024-Present)

Host, THE CHAIN: PROTEIN ENGINEERING PODCAST (2021 – Present)

Google Scholar: <https://scholar.google.com/citations?user=eeGFnbcAAAJ&hl=en>